Leading From The Lab: MIT’s Robert Langer On The Converging Science Of Drugs, Devices And Delivery
"If one has the essential ingredients of a good idea, a patent, data and some talented people, you can often start a company."
Ten years after our first encounter with MIT’s Robert Langer, In Vivo sits down with the polymath professor – arguably the most inventive and prolific life scientist of his generation – to identify key challenges in medicine.

More from Business Strategy
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
- • By
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
- • By
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
More from In Vivo
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.


